SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-80490"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-80490" > In vitro characteri...

In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics

Steffen, Ann-Charlott (författare)
Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
Wikman, Maria (författare)
Tolmachev, Vladimir (författare)
Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
visa fler...
Adams, Gregory P. (författare)
Nilsson, Fredrik Y. (författare)
Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
Ståhl, Stefan (författare)
KTH,Skolan för bioteknologi (BIO)
Carlsson, Jörgen (författare)
Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
visa färre...
 (creator_code:org_t)
Mary Ann Liebert Inc, 2005
2005
Engelska.
Ingår i: Cancer Biotherapy and Radiopharmaceuticals. - : Mary Ann Liebert Inc. - 1084-9785 .- 1557-8852. ; 20:3, s. 239-248
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The 185 kDa transmembrane glycoprotein human epidermal growth factor receptor 2 (HER-2) (p185/neu, c-ErbB-2) is overexpressed in breast and ovarian cancers. Overexpression in breast cancer correlates with poor patient prognosis, and visualization of HER-2 expression might provide valuable diagnostic information influencing patient management. We have previously described the generation of a new type of affinity ligand, a 58-amino-acid affibody (Z(HER2:4)) with specific binding to HER-2. In order to benefit from avidity effects, we have created a bivalent form of the affibody ligand, (Z(HER2:4))2. The monovalent and bivalent ligands were compared in various assays. The new bivalent affibody has a molecular weight of 15.6 kDa and an apparent affinity (K(D)) against HER-2 of 3 nM. After radioiodination, using the linker molecule N-succinimidyl p-(trimethylstannyl) benzoate (SPMB), in vitro binding assays showed specific binding to HER-2 overexpressing cells. Internalization of 125I was shown after delivery with both the monovalent and the bivalent affibody. The cellular retention of 125I was longer after delivery with the bivalent affibody when compared to delivery with the monovalent affibody. With approximately the same affinity as the monoclonal antibody trastuzumab (Herceptin) but only one tenth of the size, this new bivalent molecule is a promising candidate for radionuclide-based detection of HER-2 expression in tumors. 125I was used in this study as a surrogate marker for the diagnostically relevant radioisotopes 123I for single photon emission computed tomography (SPECT)/gamma-camera imaging and 124I for positron emission tomography (PET).

Ämnesord

NATURVETENSKAP  -- Biologi -- Mikrobiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Microbiology (hsv//eng)

Nyckelord

Amino Acid Sequence
Antibodies; Bispecific/*immunology
Biological Transport
Cell Line; Tumor
Humans
Iodine Radioisotopes
Kinetics
Ligands
Microscopy; Confocal
Molecular Sequence Data
Molecular Weight
Neoplasms/immunology/*metabolism/*radionuclide imaging
Receptor; erbB-2/chemistry/immunology/*metabolism
Research Support; Non-U.S. Gov't
Sequence Alignment
MEDICINE
MEDICIN
Microbiology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy